M. Baccarani Et Al. , "Cytogenetic and Molecular Response to Imatinib in High Risk (Sokal) Chronic Myeloid Leukemia (CML): Results of An European Leukemianet Prospective Study Comparing 400 Mg and 800 Mg Front-Line," 50th Annual Meeting of the American-Society-of-Hematology , vol.112, San-Francisco, Costa Rica, pp.75-76, 2008
Baccarani, M. Et Al. 2008. Cytogenetic and Molecular Response to Imatinib in High Risk (Sokal) Chronic Myeloid Leukemia (CML): Results of An European Leukemianet Prospective Study Comparing 400 Mg and 800 Mg Front-Line. 50th Annual Meeting of the American-Society-of-Hematology , (San-Francisco, Costa Rica), 75-76.
Baccarani, M., Castagnetti, F., Simonsson, B., Porkka, K., HAZNEDAROĞLU, İ. C., Nagler, A., ... Palandri, F.(2008). Cytogenetic and Molecular Response to Imatinib in High Risk (Sokal) Chronic Myeloid Leukemia (CML): Results of An European Leukemianet Prospective Study Comparing 400 Mg and 800 Mg Front-Line . 50th Annual Meeting of the American-Society-of-Hematology (pp.75-76). San-Francisco, Costa Rica
Baccarani, Michele Et Al. "Cytogenetic and Molecular Response to Imatinib in High Risk (Sokal) Chronic Myeloid Leukemia (CML): Results of An European Leukemianet Prospective Study Comparing 400 Mg and 800 Mg Front-Line," 50th Annual Meeting of the American-Society-of-Hematology, San-Francisco, Costa Rica, 2008
Baccarani, Michele Et Al. "Cytogenetic and Molecular Response to Imatinib in High Risk (Sokal) Chronic Myeloid Leukemia (CML): Results of An European Leukemianet Prospective Study Comparing 400 Mg and 800 Mg Front-Line." 50th Annual Meeting of the American-Society-of-Hematology , San-Francisco, Costa Rica, pp.75-76, 2008
Baccarani, M. Et Al. (2008) . "Cytogenetic and Molecular Response to Imatinib in High Risk (Sokal) Chronic Myeloid Leukemia (CML): Results of An European Leukemianet Prospective Study Comparing 400 Mg and 800 Mg Front-Line." 50th Annual Meeting of the American-Society-of-Hematology , San-Francisco, Costa Rica, pp.75-76.
@conferencepaper{conferencepaper, author={Michele Baccarani Et Al. }, title={Cytogenetic and Molecular Response to Imatinib in High Risk (Sokal) Chronic Myeloid Leukemia (CML): Results of An European Leukemianet Prospective Study Comparing 400 Mg and 800 Mg Front-Line}, congress name={50th Annual Meeting of the American-Society-of-Hematology}, city={San-Francisco}, country={Costa Rica}, year={2008}, pages={75-76} }